New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 23, 2014
07:52 EDTSGMO, IDRA, BLUE, AGTC, ISIS, CLDN, ARWR, SRPT, INO, BMRN, ALNYPiper Jaffray to hold a symposium
GenomeRX Symposium to be held in New York on June 23.
News For AGTC;ALNY;ARWR;BLUE;BMRN;CLDN;IDRA;INO;ISIS;SGMO;SRPT From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
December 9, 2014
14:31 EDTBLUEbluebird bio volatility decreases as shares rally after announcing drug trial
Subscribe for More Information
14:12 EDTBLUEbluebird bio soars after announcing drug trial results
Subscribe for More Information
12:25 EDTBLUEOn The Fly: Midday Wrap
Subscribe for More Information
12:22 EDTSGMO, ALNY, BMRNPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:19 EDTBLUEHigh option volume stocks
Subscribe for More Information
10:08 EDTBLUEHigh option volume stocks
Subscribe for More Information
09:27 EDTBLUEbluebird bio price target raised to $90 from $50 at Roth Capital
Roth Capital hiked its price target on bluebird after the company reported favorable data for its LentiGlobin drug product at ASH. The firm keeps a Buy rating on the shares.
09:21 EDTBLUE, IDRAOn The Fly: Pre-market Movers
UP AFTER EARNINGS: AutoZone (AZO), up 3.8%... Burlington Stores (BURL), up 3.3%. ALSO HIGHER: bluebird bio (BLUE), up 56.5% after price target raised at Piper Jaffray and SunTrust... Camtek (CAMT), up 6.7% after being awarded a $2.8M order from a semiconductor manufacturer... PDC Energy (PDCE), up 5.8% after providing fiscal 2015 production guidance... Mast Therapeutics (MSTX), up 3.1% after reporting that it will begin recruiting patients for MST-188 study in first half of fiscal 2015... Idera Pharmaceuticals (IDRA), up 1.4% after announcing data for its lead product candidate, IMO-8400. DOWN AFTER EARNINGS: UTi Worldwide (UTIW), down 10.8%... CONN'S (CONN), down 35.9% after reporting third quarter results, withdrawing fiscal 2015 guidance, stating that there is no timetable set for completion of strategic alternatives, and announcing the departure of its CFO. ALSO LOWER: Apple (AAPL), down 1.6% after Pacific Crest says that weak iPad demand could cause Apple to miss estimates and following a Wall Street Journal report that a judge denied Apple's efforts to throw out iPod pricing lawsuit... Allied Nevada Gold (ANV), down 30.1% after announcing pricing of common stock and warrant offering... United Continental (UAL), down 2.7% after reporting November traffic.
07:44 EDTBMRNAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
07:35 EDTBLUEbluebird bio price target raised to $115 from $57 at SunTrust
Subscribe for More Information
06:45 EDTBLUEbluebird bio price target raised to $112 from $52 at Piper Jaffray
Piper Jaffray more than doubled its price target for bluebird bio shares to $112 saying the company's LentiGlobin program is advancing in sickle cell anemia. Piper believes bluebird "remains positioned for extraordinary outperformance in 2015." The firm thinks the data presented at the American Society of Hematology are an "impressive accomplishment for the gene therapy field" as well as bluebird's lentivirus platform. It keeps an Overweight rating on the stock. Shares of the clinical-stage biotechnology company rallied yesterday $4.18 to $48.89 and are indicated up $21.11 in pre-market trading to $70.
06:38 EDTALNYAlnylam to host conference call
Conference call to discuss Phase 1 data from ALN-AT3, in development for the treatment of hemophilia will be held on December 9 at 8 am. Webcast Link
05:47 EDTALNYAlnylam reports poisitve initial results for ALN-AT3
Subscribe for More Information
December 8, 2014
17:48 EDTBLUEbluebird bio says first four patients treated with LentiGlobin transfusion-free
bluebird bio announced data from eight subjects treated with LentiGlobin BB305 drug product. In the first four subjects, each of whom had at least three months of follow up, treatment with LentiGlobin BB305 drug product resulted in sufficient hemoglobin production to reduce or eliminate the need for transfusion support among patients with beta-thalassemia major who would otherwise require chronic blood transfusions. These data include the first five subjects treated in bluebird bio’s ongoing Phase 1/2 Northstar Study and the first three subjects from its HGB-205 study. These studies include the first subjects with the beta-0/beta-0 genotype of beta-thalassemia major treated with LentiGlobin BB305 drug product and the first subject with sickle cell disease treated with gene therapy. These data are being presented today at the 56th Annual Meeting of the American Society of Hematology in San Francisco.
17:47 EDTIDRAIdera Pharmaceuticals announces data for lead product candidate IMO-8400
Subscribe for More Information
10:41 EDTISISIsis Pharmaceuticals price target raised to $81 from $62 at Piper Jaffray
Subscribe for More Information
08:32 EDTIDRATrout Group to hold events at ASH 2014
Subscribe for More Information
08:00 EDTISISIsis Pharmaceuticals price target raised to $66 from $55 at Stifel
Subscribe for More Information
07:11 EDTSGMOSangamo presents new data for Vivo Protein Replacement Platform
Sangamo announced the presentation of new preclinical data from its proprietary programs for the treatment of lysosomal storage disorders and Shire-partnered hemophilia program. These studies demonstrate the broad applicability of Sangamo's In Vivo Protein Replacement Platform for the potentially curative treatment of such diseases. The data presented at ASH from Sangamo's proprietary IVPRP applications demonstrated the efficient production, secretion and tissue uptake of functional iduronate-2-sulfatase and alpha-L-iduronidase, enzymes that are deficient in the LSDs, Hunter and Hurler's disease, respectively. Data were also presented from Sangamo's partnered program with Shire that demonstrated that therapeutic levels of Factor IX, the human clotting factor that is deficient in hemophilia B, could be generated in a dose-dependent manner in non-human primates. There were no significant alterations in circulating albumin levels. Studies in mice also demonstrated stable Factor IX production from Sangamo's IVPRP for over 1 year.
05:30 EDTISISIsis Pharmaceuticals to host conference call
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use